Phase 1 trial of N-803, an IL-15 receptor agonist, with rituximab in patients with indolent non-Hodgkin lymphoma

CONCLUSIONS: N-803 combines with mAbs to enhance tumor-targeting in patients, and warrants further investigation in combination with immunotherapies.PMID:33832946 | DOI:10.1158/1078-0432.CCR-20-4575

Source: Clinical Cancer Research - April 9, 2021 Category: Cancer & Oncology Authors: Jennifer A Foltz Brian T Hess Veronika Bachanova Nancy L Bartlett Melissa M Berrien-Elliott Ethan McClain Michelle K Becker-Hapak Mark Foster Timothy Schappe Brad Kahl Neha Mehta-Shah Amanda F Cashen Nancy D Marin Kristen McDaniels Chaz Moreno Matthew Mos Source Type: research